Stock Traders Purchase Large Volume of DaVita Call Options (NYSE:DVA)

DaVita Inc. (NYSE:DVA) was the recipient of some unusual options trading on Friday. Traders bought 11,404 call options on the stock. This is an increase of approximately 508% compared to the typical daily volume of 1,875 call options.

Hedge Funds Weigh In On DaVita

Several institutional investors and hedge funds have recently added to or reduced their stakes in DVA. Berkshire Hathaway Inc purchased a new position in shares of DaVita during the 2nd quarter worth approximately $6,425,269,000. BlackRock Inc. purchased a new stake in shares of DaVita in the second quarter valued at approximately $547,520,000. Dimensional Fund Advisors LP grew its holdings in DaVita by 5.2% during the first quarter. Dimensional Fund Advisors LP now owns 1,145,436 shares of the company’s stock worth $176,037,000 after acquiring an additional 56,336 shares during the period. Bank of America Corp DE purchased a new position in DaVita in the second quarter worth $145,057,000. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in DaVita by 114.9% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,190,000 shares of the company’s stock valued at $135,196,000 after acquiring an additional 636,191 shares during the period. Institutional investors and hedge funds own 90.12% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on DVA shares. Weiss Ratings raised DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 5th. TD Cowen upgraded DaVita from a “hold” rating to a “buy” rating and boosted their target price for the stock from $201.00 to $220.00 in a research note on Friday, August 7th. Zacks Research downgraded DaVita from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Oppenheimer set a $220.00 price objective on shares of DaVita in a report on Friday, August 7th. Finally, UBS Group increased their target price on shares of DaVita from $235.00 to $270.00 and gave the company a “buy” rating in a research report on Friday, July 10th. Four analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, DaVita has an average rating of “Moderate Buy” and a consensus price target of $233.43.

DaVita Stock Performance

DVA traded down $1.33 during trading on Friday, hitting $181.76. The stock had a trading volume of 156,183 shares, compared to its average volume of 918,086. The firm has a market capitalization of $11.60 billion, a P/E ratio of 14.85, a PEG ratio of 0.50 and a beta of 0.83. DaVita has a twelve month low of $101.00 and a twelve month high of $247.49. The company’s 50-day moving average price is $200.58 and its 200 day moving average price is $186.72.

DaVita (NYSE:DVA) last released its earnings results on Tuesday, August 4th. The company reported $4.02 EPS for the quarter, topping the consensus estimate of $3.88 by $0.14. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The company had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.50 billion. During the same quarter last year, the business earned $2.95 EPS. The business’s revenue was up 5.2% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, equities analysts expect that DaVita will post 14.57 earnings per share for the current fiscal year.

About DaVita

DaVita Inc (NYSE: DVA) is a healthcare company focused primarily on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis services for people with chronic kidney failure, including in-center hemodialysis and home-based dialysis options. Its services also include clinical care, education, nutrition support and other resources intended to help patients manage kidney disease.

DaVita also provides broader kidney-care services, including chronic kidney disease management, care coordination and support for patients who may be candidates for kidney transplantation.